In Brief This Week is a column containing news items that our readers may have missed during the week.
The firm, which now majority-owned by Life Technologies, also posted a sharp gain in its earnings before interest and taxes.
Life Tech now owns 74 percent of the synthetic gene company.
Life Technologies has made a tender offer to acquire the remaining shares of Geneart that it does not already own for around €25.5 million. The total purchase price was approximately €56 million.
The agreement gives Applied Biosystems Deutschland approximately 58 percent of GeneArt's shares.
A proposed HHS guidance for synthetic biology roughly fits a harmonization effort started by the International Gene Synthesis Consortium.
Five firms have formed the International Gene Synthesis Consortium to set gene and customer screening protocols that address security concerns.
The firm's sales increased despite the expiration of an NIH contract.
The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.
The Associated Press reports that gene-edited food may soon be for sale.
The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.
In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.